CytoMed Therapeutics Limited (NASDAQ:GDTC – Get Free Report) shares shot up 8.3% during trading on Thursday . The stock traded as high as $2.45 and last traded at $2.41. 5,716 shares traded hands during trading, a decline of 84% from the average session volume of 35,527 shares. The stock had previously closed at $2.23.
Analyst Ratings Changes
Separately, Benchmark reaffirmed a “speculative buy” rating and set a $5.00 target price on shares of CytoMed Therapeutics in a research report on Thursday, October 10th.
Get Our Latest Research Report on CytoMed Therapeutics
CytoMed Therapeutics Trading Up 8.3 %
About CytoMed Therapeutics
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.
Read More
- Five stocks we like better than CytoMed Therapeutics
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Microsoft Can Hit New All-Time Highs This Year – Here’s Why
- About the Markup Calculator
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- Business Services Stocks Investing
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
Receive News & Ratings for CytoMed Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoMed Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
